Floatz logo

Onabotulinum Toxin A

Migraine Disorder

University of AlbertaUNKNOWNPhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
89/ 100

Competitive context

100 Active assets in the Migraine Disorder cohort.

Asset / SponsorPhaseRating
Atogepant
Stanford University
Phase 4A
Naproxen
IRCCS San Raffaele Roma
Phase 4A
Rizatriptan
Antonios Likourezos
Phase 4A
Zolmitriptan
Zosano Pharma Corporation
Phase 4A
Ubrogepant
H. Lundbeck A/S
Phase 4BBB

View all 50 →

Same molecule, other indications

Onabotulinum Toxin A is also rated in:

neuralgiaActive
CCC
Indicative · Phase 2
53 / 100
View asset →
multiple sclerosisDormant
CCC
Indicative · Phase 4
51 / 100
View asset →
obesity disorderDormant
CC
Indicative · Phase 1/2
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →